This study that we presented at ASCO 22 is titled a descriptive study on the treatment and outcomes of patients with platinum-sensitive advanced BRCA or PALB2-related pancreatic cancers who have progressed on rucaparib. Basically, what this study was is a follow-up study to a phase 2 clinical trial of patients with platinum-sensitive, advanced pancreatic cancer who had a germline or somatic pathogenic variant in BRCA 1, BRCA 2, or PALB2 patients who had the platinum-sensitive disease were placed on a maintenance rucaparib treatment, which is a PARP inhibitor.

The clinical question we had was how do we treat these patients after their cancer has progressed on rucaparib in pancreas cancer. In particular, is very limited data to guide our management. So broadly, what we were interested in is looking at what patients were treated with after they've come off of the protocol study, and broadly we were interested in particular in the use of platinum-based versus non-platinum-based chemotherapies.

We looked at outcomes such as overall survival progression-free survival objective response rates by 1.1 and an endpoint called PFS 2, which we defined as the time from enrollment on the initial clinical trial until progression on the second line chemotherapy. The original clinical trial had 42 patients that had enrolled of these 42, 18 had progressed and were treated with platinum-based chemotherapy, 5 progressed and were treated with non-platinum-based chemotherapy.

11 patients at the time of data cutoff remained on the initial clinical trial. 6 patients did not receive any further therapy after progression, and 2 patients received other therapies such as targeted therapies or radiation broadly. What we found was that of the 18 patients who received platinum-based chemotherapy after progression rucaparib the median overall survival was 14.8 months.

Of those five patients who received non-platinum-based chemotherapies, the median overall survival was 28.9 months. Although there's a numerical difference here, the limited sample size prevent us from drawing any definitive conclusions about superiority, the objective response rates for those who receive platinum-based chemotherapies was 22.2%.

Whereas those who received non-platinum-based chemotherapies was 40%. We also looked at the type of platinum that patients received. If they received further platinum-based chemotherapy, there were nine patients who received a Cisplatin-based regimen and nine patients who received an Ozil platinum-based regimen.

The patients who received Cisplatin had a median overall survival of 13.8 months. And those who received oxaliplatin-based therapies had a median overall survival of 19 months. the objective response rates. For those who received cisplatin was 11.1% compared to 33.3%. For those who received oxaliplatin, we could not identify any particular patterns with regard to times that patients spent on recap, AIB, and outcomes following progression on chemotherapy.

And so the conclusion from this study was that this is a small observational study where we looked at how to treat patients following progression on chemotherapy. And although the sample size is too small to make any definitive comparisons, it does appear that chemotherapies still remain an option in select patients.

remain an option in select patients... To Read The Rest of the Transcript or Watch the Video Click Here